Supriya Patel

A PD-1-targeted, receptor-masked IL-2 immunocytokine that engages IL-2Rα strengthens T cell-mediated anti-tumor therapies

Jiaxi Wu, Nicolin Bloch, Aaron Y. Chang, Ramandeep Bhavsar et autres

The clinical use of interleukin-2 (IL-2) for cancer immunotherapy is limited by severe toxicity. Emerging IL-2 therapies with reduced IL-2 receptor alpha (IL-2Rα) binding aim to mitigate toxicity and regulatory T cell (Treg) expansion but have had limited clinical success. Here, we …

us (code pays fourni par la source)

Abstract IA012: REGN10597: A PD-1-targeted, receptor-masked wild type IL-2 with improved therapeutic window for cancer immunotherapy

Jiaxi Wu, Nicolin Bloch, Aaron N. Chang, Ramandeep Bhavsar et autres

Abstract Recombinant IL-2 has been used for the treatment of metastatic melanoma and renal cell carcinoma, and induced complete, durable tumor regression in some patients. ​However, its broader use in cancer immunotherapy has been limited by severe toxicity. Here, we describe the …

us (code pays fourni par la source)

Abstract 4434: A PD-1-targeted, receptor-masked IL-2 immunocytokine with maintained potential to engage endogenous IL-2Ra drives selective stimulation of PD-1+ T cells and robust anti-tumor efficacy

Jiaxi Wu, Nicolin Bloch, Aaron N. Chang, Ramandeep Bhavsar et autres

Abstract Interleukin-2 (IL-2) is a key cytokine for T cell proliferation, differentiation, and effector function. Recombinant IL-2 has been used for the treatment of metastatic melanoma and renal cell carcinoma, and induced complete, durable tumor regression in some patients. ​However, its broader …

us (code pays fourni par la source)

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Lauric Haber, Kara Olson, Marcus P. Kelly, Alison Crawford et autres

T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific antigens (TSA), inducing T-cell-mediated killing of tumor cells. The promising preclinical and clinical efficacy of …

us, gb (code pays fourni par la source)

Abstract 4555: Selection of CD3 affinity allows generation of T-cell redirecting bispecific antibodies with unique pharmacokinetic and biodistribution properties

Lauric Haber, Kara Olson, Robert Babb, Marcus P. Kelly et autres

Abstract T-cell redirecting bispecific antibodies are an emerging class of therapeutic agents designed to simultaneously bind to T cells (via CD3) and tumor cell specific antigens (TSA), with the goal of inducing T cell-mediated killing of tumor cells. Despite promising pre-clinical and …

us (code pays fourni par la source)

IgG1 Is Pathogenic in Leishmania mexicana Infection

Niansheng Chu, Bolaji N. Thomas, Supriya Patel, Laurence U. Buxbaum

There are >2 million new cases of leishmaniasis annually, and no effective vaccine has been developed to prevent infection. In murine infection, Leishmania mexicana, which lives intracellularly in host macrophages, has developed pathways to hijack host IgG to induce a suppressive IL-10 …

us (code pays fourni par la source)

Enhancement of tumor-to-nontumor localization ratios by hepatocyte-directed blood clearance of antibodies labeled with certain residualizing radiolabels.

Supriya Patel, Rhona Stein, Gaik Lin Ong, David M. Goldenberg et autres

UNLABELLED: To increase tumor-to-nontumor localization ratios of injected radiolabeled antibodies (Abs), several interrelated methods were used. METHODS: The model systems used were two human carcinoma xenografts grown in nude mice, targeted by antibodies RS11 (antiepithelial glycoprotein-2) or MN-14 (anticarcinoembryonic antigen). The Abs …

us (code pays fourni par la source)

Monoclonal antibodies against dopamine

Jean‐Luc Chagnaud, N. Mons, Supriya Patel, Sophie Tuffet et autres